Response Variability to P2Y12 Receptor Inhibitors: Expectations and Reality
JM Siller-Matula, D Trenk, K Schrör, M Gawaz… - JACC: Cardiovascular …, 2013 - jacc.org
P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the
secondary prevention of thrombotic events in vascular diseases. Within the past few years …
secondary prevention of thrombotic events in vascular diseases. Within the past few years …
Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update
Cytochrome P450 (CYP) 2C19 catalyzes the bioactivation of the antiplatelet prodrug
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
clopidogrel, and CYP2C19 loss‐of‐function alleles impair formation of active metabolites …
Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
Context High platelet reactivity while receiving clopidogrel has been linked to cardiovascular
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …
events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue …
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
JL Mega, W Hochholzer, AL Frelinger, MJ Kluk… - Jama, 2011 - jamanetwork.com
Context Variants in the CYP2C19 gene influence the pharmacologic and clinical response
to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. Objective …
to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel. Objective …
Clinical application of cardiovascular pharmacogenetics
D Voora, GS Ginsburg - Journal of the American College of Cardiology, 2012 - jacc.org
Pharmacogenetics primarily uses genetic variation to identify subgroups of patients who
may respond differently to a certain medication. Since its first description, the field of …
may respond differently to a certain medication. Since its first description, the field of …
High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2)
Objectives: This study sought to determine whether the pharmacokinetic (PK) and
pharmacodynamic (PD) responses to high or standard clopidogrel loading doses (LDs) …
pharmacodynamic (PD) responses to high or standard clopidogrel loading doses (LDs) …
Effect of CYP2C19*2 and *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated …
Background—As compared with whites, East Asians more often carry the cytochrome P450
(CYP) 2C19 loss-of-function (LOF) allele with the CYP2C19* 3 variant. The influence of the …
(CYP) 2C19 loss-of-function (LOF) allele with the CYP2C19* 3 variant. The influence of the …
Prasugrel Overcomes High On-Clopidogrel Platelet Reactivity Post-Stenting More Effectively Than High-Dose (150-mg) Clopidogrel: The Importance of CYP2C19*2 …
D Alexopoulos, G Dimitropoulos, P Davlouros… - JACC: Cardiovascular …, 2011 - jacc.org
Objectives: The primary aim of the study was to determine the antiplatelet effects of
prasugrel versus high-dose clopidogrel in patients with high on-treatment platelet reactivity …
prasugrel versus high-dose clopidogrel in patients with high on-treatment platelet reactivity …
Platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents
1276 onstrated the strong relation between the occurrence of stent thrombosis and
clopidogrel nonresponsiveness or HPR. 4 The prothrombotic effects of the P2Y12 platelet …
clopidogrel nonresponsiveness or HPR. 4 The prothrombotic effects of the P2Y12 platelet …
ABCB1 C3435T Polymorphism and Response to Clopidogrel Treatment in Coronary Artery Disease (CAD) Patients: A Meta-Analysis
J Su, J Xu, X Li, H Zhang, J Hu, R Fang, X Chen - 2012 - journals.plos.org
Background A number of investigators have evaluated the association between the ABCB1
polymorphism and clopidogrel responding, but the results have been inconclusive. To …
polymorphism and clopidogrel responding, but the results have been inconclusive. To …